IMR Press / RCM / Volume 8 / Issue S2 / pii/1561094459964-1735709833

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
The Efficacy of Aliskiren, a Direct Renin Inhibitor, in the Treatment of Hypertension
Show Less
1 Division of Cardiovascular Diseases, The Western Pennsylvania Hospital and Temple University School of Medicine (Clinical Campus), Pittsburgh, PA
Rev. Cardiovasc. Med. 2007, 8(S2), 22–30;
Published: 20 February 2007
Abstract
Aliskiren is a potent, highly specific renin inhibitor with better oral bioavailability than earlier renin inhibitors and a long plasma half-life that makes it suitable for once-daily dosing. The efficacy and safety of aliskiren in treating hypertension has been studied in clinical trials both as monotherapy, comparing it with existing antihypertensive therapies, and in combination with other antihypertensive agents, including the diuretic hydrochlorothiazide, the angiotensin-converting enzyme inhibitor ramipril, and the calcium channel blocker amlodipine. From the extensive database acquired to date, it is clear that aliskiren is an effective antihypertensive agent, with once-daily administration resulting in dose-dependent systolic and diastolic blood pressure reductions. Combinations with existing antihypertensives are producing promising additional blood pressure–lowering effects.
Keywords
Aliskiren
Renin inhibitors
Hypertension
Antihypertensives
Share
Back to top